RBC Capital downgrades Sonova stock rating on valuation concerns. Published Nov 06, 2026, 01:44 AM (C) Reuters Investing.com - RBC Capital downgraded Sonova Holding AG (SOON:SW) (OTC:SONVY) to Sector Perform from Outperform on Friday while raising its price target to CHF283.00 from CHF250.00. Analyst Charles Weston noted that Sonova shares have risen almost 70% in the last six months in anticipation of revenue growth acceleration from a recovering market and new product launches. The stock currently trades at $71, just shy of its 52-week high of $71.91, with InvestingPro data showing a 53% six-month return. An InvestingPro Tip notes the RSI suggests overbought territory, while the stock trades at a P/E ratio of 32.45. The firm rolled forward its price target to CHF 283 at end-2027. The analyst acknowledged that the timing may be risky ahead of next week's H1 F2026/27 results as management is likely to be in a buoyant mood when discussing the EON launch. RBC Capital said it prefers to be on the sidelines until the trajectory becomes clearer. EON was launched a few weeks before the period end. Weston said qualitative commentary around customer and audiologist feedback will be critical, alongside anything on Costco and VA early traction and potential stocking dynamics. The company's current FY guidance is 5-8% CC sales growth and 7-10% core EBIT growth. Any commentary about the potential timing for a Zeal competitor product launch and Integro launch timing will also be important, the analyst said. In other recent news, Sonova Holding AG has been the focus of several analyst updates. Goldman Sachs has upgraded Sonova to Buy from Neutral, raising its price target to CHF315, anticipating above-market growth in the first half of fiscal 2027. The firm expects the company to achieve approximately 9% constant currency revenue growth, surpassing the Visible Alpha Consensus Data of 6%. Meanwhile, Deutsche Bank has maintained a Hold rating on Sonova but increased its price target to CHF253, driven by an 8.8% forecasted constant-currency sales growth, with notable momentum in hearing aids. This growth is expected to be offset by declines in hearing implants. UBS, on the other hand, downgraded Sonova to Neutral from Buy, despite raising its price target to CHF293. UBS noted strong fundamentals supported by a recovering U.S. hearing aid market and a competitive new platform. These recent developments provide a range of perspectives on Sonova's potential performance in the coming months. Included in its AI-picked strategies -7.00 (-2.40%) Real-time Data · 04:07:33 · CHF What's your entry and stop on SOON? Your pre-market routine takes 20 minutes and three tools. By the time you're done, the setup on SOON can be gone. AI chart analysis reads the SOON chart in under 60 seconds. It scans 15 indicators, surfaces only the ones that matter right now, and hands you a trading plan with entry, stop-loss and profit targets. Set a custom alert on those levels and you'll know the moment SOON hits them. Works across multiple intraday timeframes, on 94,000+ assets. Now 55% off for Black Friday early birds.

NAD addresses whether advertisers can use AI to substantiate claims. October 19, 2026 In a recent NAD case, hearing aid maker Sonova challenged a series of claims that competitor Starkey made about its Omega AI hearing aid. The decision covers a lot of ground - including what constitutes an ad and how companies should substantiate preference claims - but this post will focus on one question: can a company use AI testing to back up claims that its product beats the competition? Starkey claimed that Omega AI was "better than the rest in noisy conditions" and delivered "up to a 6.5 dB advantage (70% improvement)" in speech intelligibility compared to all major brands. To support these claims, Starkey put various hearing aids on a dummy head, recorded their output in noisy settings, and had Whisper, an AI speech-to-text tool, measure how many words it recognized. The parties disagreed over whether the use of AI, rather than actual humans, to test the product was sufficient. Starkey argued that AI testing is consistent, objective, and removes the variation that comes with human test subjects. Moreover, the use of AI allows for a larger number of measurements than humans would tolerate, resulting in better predictions of real-world performance. In a key paragraph, NAD wrote: "AI testing for claims substantiation is an emerging area with many potential benefits, which should be accommodated, but there must be evidence that the testing has been properly validated for the claims being supported, especially when those claims assert real-world consumer benefits." NAD determined that validation was missing. NAD found that consumers would read "speech intelligibility" and "noisy conditions" as promises about real-world performance. But nothing in the record showed that Whisper's results match what actual hearing aid wearers experience. Starkey's own paper admitted that more work was needed to establish whether AI-based measurements are valid. Adding the word "predictive" to the claim helped, but it was not enough. NAD flagged another concern with the claim: competitive claims must be based on current data. By the time of the challenge, four of the five competing brands Starkey tested had already updated their flagship models. NAD recommended discontinuing the claims, while making clear that Starkey may still use AI to support "carefully tailored claims." The takeaway for advertisers is that although NAD is open to AI-based testing, validation is necessary. Before relying on AI to support a claim, companies should confirm that the testing method reflects how real consumers will experience the product. Advertisers should also make sure their competitive testing reflects the current market and be prepared to adapt as the market changes.

Sonova launches AI products. Goldman upgrades Sonova stock to Buy. Published on 10/18/2026 at 13:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Sonova extends AI beyond hearing aids on October 14, 2026. Sonova stock has a CHF315.00 Goldman target after CHF230.00 before November results. AI expansion and earnings dates. * Sonova introduced Roger On Sphere and Integro on October 14, 2026. * Goldman Sachs set a CHF 315.00 target after CHF 230.00 on October 8, 2026. * Fiscal year 2025/26 sales reached CHF 3,605.9 million, up 5.9 percent in local currencies. * Sonova is scheduled to report first-half fiscal 2027 results on November 12, 2026. Sonova Holding AG (ISIN CH0012549785) introduced new artificial-intelligence products on October 14, 2026, extending its technology beyond hearing aids. According to Financial Times, the Roger On Sphere remote microphone and Advanced Bionics Integro sound processors broaden Sonova's AI offering across hearing aids, wireless communication and cochlear implants. Discover more hearing devices Hearing Aids AI moves beyond hearing aids. Roger On Sphere uses real-time AI to separate speech from background noise and is designed to connect directly with compatible hearing devices without external receiver hardware. The product is scheduled to become available from mid-November 2026, while Integro has received TÜV approval and is being introduced in selected European markets, according to the same October 14 company announcement. What does the target imply? Goldman Sachs upgraded Sonova from Neutral to Buy on October 8, 2026, and raised its price target from CHF 230.00 to CHF 315.00. Investing.com reported that the bank expects constant-currency revenue growth of 7.8 percent in fiscal 2027, compared with 6.6 percent consensus, and adjusted EBIT growth of 12.6 percent versus 6.5 percent consensus. The target change gives investors a quantified measure of how sharply the bank's view improved. Three milestones frame the story. Sonova reported fiscal year 2025/26 sales of CHF 3,605.9 million, up 5.9 percent in local currencies, in its May 18, 2026 results release, according to the company's official newsroom. Goldman Sachs followed with its October 8 target change, and Sonova then presented the October 14 product expansion. The sequence links a proven growth base with a fresh technology push. Discover more Try Assistive Tech Shop Ham Radios Next dates for shareholders. Investing.com identified November 12, 2026 as the date for Sonova's first-half fiscal 2027 results. Roger On Sphere is expected from mid-November 2026, creating two closely timed milestones for assessing product uptake and the company's growth outlook. Stock context and investor takeaway. Sonova's reported sales growth, the CHF 315.00 target and the planned November results date give the stock a defined set of company-specific reference points. The key question is whether the AI portfolio can translate technical differentiation into broader adoption and sustained revenue growth. Sonova stock key facts. * Company: Sonova Holding AG * ISIN: CH0012549785 * Ticker: SOON * Primary exchange: SIX Swiss Exchange * Sector / Industry: Healthcare / Medical Devices * CEO: Eric Alain Bernard Discover more Invest in Stocks Find Care Aids Sponsored Ad Sonova stock: new analysis - 21 October. Fresh Sonova information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | CH0012549785 | SONOVA HOLDING AG | boerse | 70353592 | bgmi